Clinical and design update on the development and testing of a one-piece, bifurcated, polytetra-fluoroethylene endovascular graft for abdominal aortic aneurysm exclusion: the Endologix device.
Continued success and expanding use of endovascular prostheses to manage aortic aneurysms has encouraged development of novel prototypes that offer advantages for low-profile delivery of durable devices. The Endologix device, currently being acquired by CR Bard, Incorporated, is a new, one-piece self-expanding polytetrafluoroethylene prosthesis that offers an alternative to current modular and fabric devices. Although only preliminary U.S. and expanding European experiences are available, the unique features of this prosthesis appear to offer an appealing alternative.
White
R A
RA
Division of Vascular Surgery, Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
D000368:Aged; D000369:Aged, 80 and over; D017130:Angioplasty / Q000009:adverse effects / Q000295:instrumentation*; D017544:Aortic Aneurysm, Abdominal / Q000000981:diagnostic imaging / Q000601:surgery*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects / Q000592:standards*; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011138:Polytetrafluoroethylene; D011474:Prosthesis Design; D011475:Prosthesis Failure; D011859:Radiography; D015607:Stents / Q000009:adverse effects / Q000592:standards*; D013997:Time Factors; D016896:Treatment Outcome
D011138:Polytetrafluoroethylene